Historical Context & Motivation
Pharmacy compounding has ancient roots — pharmacists have prepared individualized medications for centuries — but the formal regulation of compounding records is a relatively modern development driven by patient safety crises. Throughout much of pharmacy history, compounding was the primary means of dispensing medications, and pharmacists relied on personal expertise and informal logs. However, as the pharmaceutical industry matured and large-scale manufacturing emerged in the twentieth century, compounding was increasingly marginalized until a series of contamination events and adverse outcomes demonstrated that unregulated compounding posed serious public health risks. These tragedies catalyzed federal and state legislatures into action, producing the layered regulatory framework that governs compounding documentation today.
The central question that compounding record-keeping requirements address is straightforward yet profound: how can we ensure that every compounded preparation is traceable, reproducible, and safe? Without rigorous documentation, a pharmacy cannot verify that a preparation was made correctly, investigate an adverse event, recall a defective batch, or demonstrate compliance during a board of pharmacy inspection. The regulatory answer lies in a multilayered system of master formulation records, compounding records, standard operating procedures, and hazardous drug handling documentation governed by USP chapters, state pharmacy practice acts, and federal law.
Core Principles & Definitions
Compounding record-keeping is built upon a hierarchy of documentation that serves distinct but interconnected purposes. At its foundation, the system requires that every preparation can be traced from the raw ingredients through the compounding process to the final dispensed product and ultimately to the patient. This traceability principle is not merely a regulatory formality; it is a patient safety imperative that enables root-cause analysis when problems arise. Understanding the core documents and the regulatory authorities that mandate them is essential for both MPJE preparation and competent pharmacy practice.
Master Formulation Record (MFR)
Compounding Record (CR)
Standard Operating Procedures (SOPs)
Beyond-Use Date (BUD)
Hazardous Drug Documentation
Visual Explanation — The Documentation Hierarchy
The diagram above illustrates how compounding documentation is structured as a layered system of accountability. At the apex, regulatory authorities — including the FDA, state boards of pharmacy (BOP), the USP, and the DEA — establish the standards that drive every document below. Standard Operating Procedures and USP <800> hazardous drug documentation set the facility-wide baseline. The Master Formulation Record serves as the approved template for a given preparation, while the Compounding Record captures batch-specific execution data. Together, these documents create an unbroken chain from regulatory intent to patient outcome. Note how hazardous drug records feed into the compounding record as an overlay — hazardous compounding requires all standard documentation plus additional safety records.
Regulatory Mechanism — USP Chapters, Federal Law & State Requirements
Compounding record-keeping requirements derive from three overlapping sources of authority, and understanding their interplay is essential for MPJE success. USP General Chapters set enforceable standards once adopted by state boards of pharmacy. The revised USP <795> (non-sterile compounding) and USP <797> (sterile compounding) specify the exact contents of master formulation records and compounding records, while USP <800> overlays hazardous drug handling requirements on top of both. Federal law — specifically Section 503A and Section 503B of the FDCA — distinguishes traditional pharmacy compounding from outsourcing facility production, with markedly different documentation requirements. State pharmacy practice acts then adopt, modify, or exceed these standards, creating a patchwork that the MPJE tests heavily.
USP <795> — Non-Sterile Compounding Documentation
- Master Formulation Record must include: official or assigned name and strength, dosage form, ingredient identities and quantities, equipment required, detailed mixing instructions, packaging and storage specifications, assigned BUD with rationale, and quality control (QC) procedures.
- Compounding Record must include: date and time of preparation, MFR reference, names and quantities of actual ingredients used, lot numbers and expiration dates of each ingredient, total quantity compounded, assigned BUD, compounder identification, pharmacist verification, and QC results (appearance, weight, pH, etc.).
USP <797> — Sterile Compounding Documentation
Sterile compounding adds environmental monitoring records, media fill test results, gloved fingertip sampling data, and viable and nonviable air sampling logs to the documentation requirements of <795>. The compounding record for a sterile preparation must additionally document the ISO-classified environment in which it was prepared, endotoxin testing results (for high-risk preparations), and sterility testing results where applicable. Assigned BUDs for sterile compounding are significantly more conservative than for non-sterile preparations and vary based on the category of compounded sterile preparation (CSP) — Category 1 versus Category 2 — as defined in the revised <797>.
USP <800> — Hazardous Drug Handling Documentation
USP <800> requires entities handling hazardous drugs (HDs) to maintain a comprehensive assessment of risk based on the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. Documentation must include the list of HDs handled by the facility, containment primary engineering control (C-PEC) and containment secondary engineering control (C-SEC) certification records, personnel training and competency assessment logs, medical surveillance records, spill incident reports, and hazardous waste disposal manifests. The standard also requires that HDs be stored, prepared, and disposed of in designated areas, with written SOPs describing each process. Notably, USP <800> applies to all healthcare settings that handle HDs — not just pharmacies that compound them — making its documentation scope broader than <795> or <797>.
503A vs. 503B — Federal Distinctions
| Requirement | 503A Pharmacy | 503B Outsourcing Facility |
|---|---|---|
| Prescription required? | Yes — patient-specific Rx | No — may compound without Rx |
| FDA cGMP inspection? | No (state BOP oversight) | Yes — subject to FDA cGMP |
| Adverse event reporting? | State-level requirements | Mandatory FDA MedWatch |
| Labeling requirements | Patient-specific label | Product-specific label with lot # |
| Record retention | Per state law (often 2–5 years) | FDA-mandated (typically ≥ 3 years) |
Detailed Breakdown — Required Elements of Compounding Records
While the high-level distinction between the Master Formulation Record and the Compounding Record is foundational, the MPJE frequently tests knowledge of the specific data elements required in each document. The following diagram and table present the mandatory elements side by side, highlighting the critical differences between template-level and batch-level documentation.
Worked Example — Completing a Compounding Record
Consider the following scenario: A community pharmacy operating under Section 503A receives a prescription for a patient-specific compound — Progesterone 100 mg vaginal suppositories, quantity of 30. The pharmacy has an existing MFR on file. The pharmacist and technician must now generate a compliant Compounding Record for this batch. Let us walk through the documentation process step by step.
Strengths, Limitations & Regulatory Comparisons
The current compounding record-keeping framework represents a significant advance in patient safety, but it is not without limitations. Understanding both the strengths and the gaps in the system is critical for pharmacists who must navigate real-world compliance challenges and for MPJE candidates who encounter questions about regulatory shortcomings and reform proposals.
| Aspect | Strengths | Limitations |
|---|---|---|
| Traceability | Lot-level ingredient tracking enables full root-cause analysis in adverse events | Paper-based systems in smaller pharmacies may be incomplete or illegible |
| Reproducibility | MFRs ensure any qualified compounder can reproduce the preparation identically | No universal MFR template; variability across pharmacies reduces standardization |
| Regulatory Consistency | USP chapters provide uniform national standards when adopted by states | State-by-state adoption creates a patchwork; not all states adopt revised USP chapters simultaneously |
| Hazardous Drug Safety | USP <800> provides comprehensive personnel protection documentation requirements | Enforcement varies; some states have delayed or partially implemented <800> |
| Federal Oversight | 503B outsourcing facilities face rigorous FDA cGMP inspection | 503A pharmacies rely on state inspection frequency, which varies widely |
Connection to Advanced Regulatory Theory — cGMP, FDA Modernization & Evolving Standards
The compounding record-keeping framework studied in this lesson exists on a continuum with current Good Manufacturing Practice (cGMP) regulations that govern pharmaceutical manufacturers. While 503A pharmacies operate under USP standards and state pharmacy practice acts, 503B outsourcing facilities are held to cGMP standards that mirror those of drug manufacturers. Understanding where compounding record-keeping sits on this spectrum — and how regulatory expectations are evolving — prepares students for advanced pharmacy law coursework, residency training, and the increasingly complex questions appearing on the MPJE.
| Feature | 503A Compounding (USP-Based) | 503B / cGMP (FDA-Based) |
|---|---|---|
| Batch record complexity | Single-page CR tied to MFR | Multi-page batch production record with in-process controls |
| Stability testing | BUD assigned from USP defaults or literature | Formal stability studies (ICH guidelines) required for expiration dating |
| Environmental monitoring | Required for sterile (USP <797>) compounding | Required for all dosage forms; continuous monitoring with trend analysis |
| Change control documentation | MFR revision tracked informally | Formal change control system with impact assessments |
| Deviation documentation | Noted on CR; pharmacist determines disposition | Formal deviation reports with CAPA (corrective and preventive action) plans |
Looking forward, the trend is clearly toward more rigorous documentation requirements even for traditional 503A pharmacies. The revised USP <795> and <797> chapters — expected to be fully enforceable once implementation dates are finalized — significantly expand documentation expectations compared to their predecessors. Electronic compounding record systems are becoming standard, enabling automated lot tracking, real-time BUD calculations, and integrated audit trails. For MPJE candidates, the key insight is that compounding documentation is not static; it evolves with each revision of USP standards and each legislative reform. Staying current with your practicing state's adoption timeline for USP chapters is an ongoing professional obligation that extends well beyond licensure.
Practice Problems
Summary — Compounding Records & Hazardous Materials Documentation
Compounding record keeping is built upon two foundational documents: the Master Formulation Record (MFR), which serves as the pre-approved recipe for a compounded preparation, and the Compounding Record (CR), which documents the batch-specific execution of that recipe. These documents are governed by USP <795> (non-sterile), USP <797> (sterile), and USP <800> (hazardous drugs), with federal distinctions between Section 503A traditional pharmacies and Section 503B outsourcing facilities establishing different documentation obligations.
Key elements of the CR include ingredient lot numbers and expiration dates, compounder identification, pharmacist verification, the assigned beyond-use date (BUD), and quality control results. For hazardous drug compounding, pharmacies must additionally maintain risk assessments, engineering control certifications, personnel training logs, medical surveillance records, and spill documentation. The governing principle for the MPJE is that the most restrictive applicable standard — whether federal, state, or USP — always controls.